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Abstract: The condition of Type 1 Diabetes Mellitus (T1DM) occurs when the pancreas 
behaves abnormally, disabling insulin production. Therefore, glucose is not metabolized as 
a natural source of energy and remains in the bloodstream. This disease causes thousands 
of deaths around the world. Health sectors, as well as the scientific community, have 
strengthened efforts to provide effective treatments. In this work, an innovative neuro-fuzzy 
control approach for blood glucose regulation in T1DM virtual patients is discussed, 
defined the membership functions in order to determine the rate of insulin infusion for 
avoiding hyperglycemia and hypoglycemia events. Additionally, a rapid prototyping of the 
proposed control scheme is carried out by programming the proposed controller into the 
LAUNCHXL-F28069M development board from Texas Instruments Inc. Application of 
such prototype is done using the Uva-Padova simulator. The Control Variability Grid 
Analysis (CVGA), obtained from the Uva/Padova simulator clearly exhibits a satisfactory 
performance for the reduction of hyperglycemia and hypoglycemia events in a population 
of 10 virtual adults. This paper aims to expand diabetes research towards developing the 
Artificial Pancreas (AP) as a programmable device. 
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Resumen: La condición de Diabetes Mellitus Tipo 1 (DMT1) ocurre cuando el páncreas 
se comporta de manera anormal e impide la producción de insulina parcialmente o 
totalmente. Por lo tanto, la glucosa no es metabolizada para convertirse en una fuente 
natural de energía y permanece en el torrente sanguíneo. Esta enfermedad causa miles de 
muertes alrededor del mundo. Los sectores de salud, así como la comunidad científica, han 
fortalecido los esfuerzos para proporcionar tratamientos más efectivos. En este trabajo, se 
expone un novedoso enfoque de control neuro-difuso para la regulación de la glucosa en 
sangre en pacientes virtuales con DMT1. La estrategia es diseñada tal que las funciones de 
membresía están definidas para determinar la tasa de infusión de insulina para evitar 
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eventos de hiperglucemia e hipoglucemia. Adicionalmente, se lleva a cabo un prototipado 
rápido programando la ley de control óptimo inverso en la tarjeta de desarrollo 
LAUNCHXL-F28069M de Texas Instruments Inc. El análisis de la variabilidad de control 
(Siglas en inglés CVGA) obtenido a través del simulador Uva/Padova muestra claramente 
un desempeño satisfactorio para la reducción de hiperglucemia e hipoglucemia en una 
población de 10 adultos virtuales. De esta manera, el trabajo tiene como objetivo expandir 
la investigación de la diabetes hacia el Páncreas Artificial (PA) como un dispositivo 
programable. 
 





The most recent report of the International 
Diabetes Federation specifies that approximately 
425 million people have diabetes, and in 2045 this 
number will grow to 629 million (George et al, 
2015). This disease caused 4 million deaths and a 
health expenditure of at least US $727 billion 
dollars in 2017. Particularly, Type 1 Diabetes 
Mellitus (T1DM) is a severe metabolic condition 
where the pancreas is not able to produce enough 
insulin to keep control of glucose levels inside an 
att healthy range. This situation is caused by 
autoimmune destruction of β-cells, responsible of 
insulin pancreatic production. Moreover, T1DM 
increases the risk of cardiovascular diseases, 
retinopathy, nephropathy, neuropathies and the 
consequences with result from them as congestive 
heart failure and diabetic foot (Tuomilehto et al, 
2015). These complications are associated with 
considerable morbidity, life ability reduction, 
physical disability and premature mortality (T. D. 
Control and C. T. R. Group, 1993). The discovery 
of insulin was revolutionary and innovative; until 
today the most common therapy is insulin 
injections to provide the body with such a 
hormone that is no longer produced. The insulin 
dose is calculated based on diet and a priori 
knowledge of the patient condition; thus, blood 
glucose monitoring is carried out manually by 
fingersticks which limit the tests number per day 
(Majithia et al, 2018). Hence, the scientific 
community is looking for all possible ways to 
bring an improving treatment; recently the 
concept of an Artificial Pancreas (AP) has arisen, 
which is, an automated closed-loop delivery 
system composed of three components: a glucose 
sensor, an infusion pump, and a computational 
procedure. It is intended that this procedure 
regulates glucose levels through automatic 
adjustments of insulin infusion and glucose 
measurements (Hovorka, 2005; U. D. of Health et 
al, 2011). Different efforts have been proposed for 
glycemic control. A model predictive control 
(MPC) approach for blood glucose regulation is 
proposed in (Magni et al, 2009); with promising 
results when tested in the UVa/Padova 
environment. In (Patek et al, 2012) a high-order 
sliding modes algorithm is used to regulate the 
blood glucose in T1DM; robust results are 
obtained with high precision in presence of 
physical disturbances such as ingestion of food 
and parametric uncertainty. A novel monitor is 
proposed in (Galadanci et al, 2012), which takes 
glucose readings, and through pattern recognition, 
the control law adapts to prevent hyperglycemic 
episodes in presence of disturbances as meal 
intake. Non-linear control strategies are 
developed in (Kovács, 2011) in order to track 
asymptotically the output of a mathematical 
model which describes glucose-insulin interaction 
for T1DM patients. 
 
In this paper, an inverse optimal control (IOC) 
approach via a Lyapunov function is considered 
to compute insulin infusion for T1DM patients; a 
Recurrent High-Order Neural Networks 
(RHONN), trained by an Extended Kalman Filter 
(EKF), captures the complex glucose-insulin 
dynamics. Additionally, a rapid prototyping in the 
LAUNCHXL-F28069M development board from 
Texas Instruments Inc allows to program and 
debug the optimal control law. It can be clearly 
seen that included fuzzy inference improves 
insulin control action. The validation carried out 
using the Uva/Padova simulator illustrates that the 
proposed controlled scheme is able to keep blood 
glucose within safe ranges. It is expected that this 
neuro-fuzzy optimal control will expand diabetes 
research towards programmable devices in order 
to develop the Artificial Pancreas. 
 
 
2. ON-LINE DISCRETE TIME NEURAL 
NETWORK 
 
The study the discrete-time neural model is 
reviewed in different publications (Alanis et al, 
2007; Rovithakis and Christodoulou, 2012; Leon 
et al, 2013; Romero-Aragon et al, 2014; Quintero-
Manriquez et al, 2017; Rios et al, 2018); this 
paper uses theoretical fundamentals for Recurrent 
High Order Neural Networks (RHONN) as 
developed in (Rios et al, 2018). 
 
Glucose-Insulin biological process is a positive 
system, i.e., its states, initial conditions, inputs, 
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and outputs are always nonnegative (Leon et al, 
2013). According to this fact, an unknown 
discrete-time disturbed positive nonlinear system 
is considered as follows, 
 
1 ( ) ( ) ( ),k k k kx f x g u d x                       (1) 
 
where 
13x is the system state at time 
 0k  , u  is a control input vector, 
( )f and ( )g  are unknown nonlinear maps and 
( )d characterizes unknown external 
disturbances and parameter variations; such is 
identificated using an RHONN as follows,  
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where w  is an adjustable parameters vector and 
'w  is a fixed weight vector, which is used to 
ensure controllability of the neural model as 
proposed in (Rovithakis and Christodoulou, 
2012). 
1, 1 1k kx G   and 2, 1k kx G   are the 
estimated variables of glucose level, ku  is the 
insulin dose. In order to minimize the prediction 
error, an EKF in the RHONN training to find the 
optimal weights values is used, which is given by 
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  is the Kalman gain matrix, 
i iL L
iP R




  is a derivatives 
matrix of neural network state ix  respecting the 
neural network weights vector 
,i jw , 1,...,i n ,  
1,...,j l , m m
iR R
  is the measurement 
noise associated covariance matrix, i
L
iw R  is 
the weight vector, i  is a design parameter, 
ie R  is the respective identification error, 
i iL L
iQ R
  is the states noise associated 
covariance matrix, and iL  is the number of neural 
network weights. iP , iQ , and iR  are initialized 
as diagonal matrix. The learning convergence and 
robustness in (Alanis et al, 2007) are analyzed.  
 
The used RHONN scheme is illustrated in Fig. 1; 
the Uva/Padova simulator constitutes the T1DM 
virtual patient, such simulator was in 2008 by the 
Food and Drug Administration (FDA) for the 
preclinical testing of control strategies to be used 
by the Artificial Pancreas, (Kovatchev et al, 2009; 
Man et al, 2014) and was developed by 
researchers at University of Virginia, USA and 
University of Padova, Italy. The academic version 
includes a thirty patients population (ten children, 
ten adolescents, and ten adults). 
 
For T1DM treatment the main objective is 
hyperglycemic and hypoglycemic events 
preventing. According to this fact, a neural multi-
step predictor (MSP) is proposed, which obtains a 
predicted glucose level withing a prediction 
horizon of fifteen minutes.  
 




Inverse Optimal Control (IOC) is applied in 
different fields (Sanchez and Ornelas-Tellez, 
2016; Li et al, 2011; Freeman and Kokotovic, 
2008; Ornelas et al, 2011a; Ornelas et al, 2011b). 
In (Ornelas et al, 2011a; Rios et al, 2018), this 
approach is analyzed, using a Control Lyapunov 
Function (CLF) to determinate a control law 
which minimizes a cost function, i.e., the glucose 
level is controlled using the minimal amount of 
supplied insulin. 
 
Let consider a positive nonlinear system 
 
   1 0( ) x =x 0 ,k k k kx f x g x u          (6) 
 
where 
13x is the system state at time 
 0k  , u is a control input vector, 
( )f and ( )g  are unknown nonlinear maps. 
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, ,k k kz x x                                                  (8) 
 
1 , 1,( ) ( )k k k k kz f x g x u x                       (9) 
 
where     0Tk kR z R z   is a matrix-valued 
function for all kx , ,kx  is the desired trajectory, 
n
kz R  is the tracking error. In (¡Error! No se 
encuentra el origen de la referencia.) using 
(¡Error! No se encuentra el origen de la 
referencia.) for reaching the trajectory, a 
definition is proposed as follows (Ornelas et al, 
2011a): 
Definition 1: Consider the tracking error as 
(¡Error! No se encuentra el origen de la 
referencia.). The control law defined in (¡Error! 
No se encuentra el origen de la referencia.) will 
be inverse optimal stabilizing along the desired 
trajectory  
,kx  if: 
 
i. for system 
¡Error! achieves (global) asymptotic 
stability of 0kx  , along reference 
,kx ;  
ii. 
 kV z  is (radially unbounded) positive 
definite function such that the inequality 
     1: 0,
T
k k k k kV V z V z u R z u
 








Considering Definition 1, and in order to satisfy 
conditions (i) and (ii), the function  kV z  is a 








k k kV z z Pz P P              (10) 
 
In order to ensure stability of the tracking error kz  
in (¡Error! No se encuentra el origen de la 
referencia.), we substitute (¡Error! No se 
encuentra el origen de la referencia.) in the 
optimal control law (¡Error! No se encuentra el 
origen de la referencia.), to obtain 
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Considering (¡Error! No se encuentra el origen 
de la referencia.) as a positive system [¡Error! 
No se encuentra el origen de la referencia.], the 
optimal control law is rewritten as  
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Fig. 2. Block diagram of closed-loop control 
system with prediction. 
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Fig. 2. Block diagram of closed-loop control 
system with prediction  
 
                                       
In (¡Error! No se encuentra el origen de la 
referencia.), V(•) is a CLF; this control law is 




 1P ,  2 kP x  are positive definite 
symmetric matrices and 
 
 
   2( ) 0,k kR z P x   which ensures the 
existence of the inverse in (12). The proposed 
scheme is illustrated in Fig. 2. Glucose level is 
regulated using a total insulin amount k
u
, which 
by the optimal control law in (12) and the 
predicted glucose level k t
   ( 15t  minutes) is 
estimated; k
u
 is a fuzzy controller with the 
structure following 
 








Hbasal, for 300mg/dL 250mg/dL
 basal, for 260mg/dL 170mg/dL
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ku  is calculated by (12) and Hbasal, basal 
are defined in Table ¡Error! No se encuentra el 
origen de la referencia.. These fuzzy sets are 
llustrated in fig. ¡Error! No se encuentra el 
origen de la referencia..  
 
 
4. PROTOTYPING AND EXPERIMENTAL 
RESULTS 
 
Rapid prototyping is developed in two stages. The 
first one is the programming stage, i.e., the NF-
IOC algorithm into a board is debugged and 
downloaded. This device is the LAUNCHXL-
F28069M development board from Texas 
Instruments Inc. The second one is the 
communication stage, Uva/Padova Simulator 
with LAUNCHXL-F28069M are linked. 
Uva/Padova simulator runs on a desktop 
computer, which includes the virtual patients, 
aglucose sensor, and an insulin pump. In this 
application, ten adults are analyzed.  
The proposed scheme for the programming stage 
is illustrated in Fig. 4. In this scheme, the 
controller is implemented via Matlab & Simulink 
of Mathworks® using a Serial Communication 
Interface (SCI) with a baud rate 
/921600 bits s
. 
Once the NF-IOC is programmed into the board, 
the communication stage is developed. For this 
stage, a serial communication protocol with the 
same baud rate that the programming one is 
configured. This protocol sends and receives data 
in real-time of the glucose-insulin system between 
the Uva/Padova simulator and the LAUNCHXL-
F28069M board. The whole closed-loop control is 
presented in Fig. 5. 
 
In order to illustrate the connection between Uva-
Padova Simulator and the Texas Instruments 
board, a picture of a virtual patient running on the 
desktop computer and the implemented controller 
into the LAUNCHXL-F28069M is displayed in 
Fig. 6. 
The carbohydrates grams (gCH) per day intake, 
and the basal infusion rate are described in Table 
1, This gCH is according to a balanced diet for a 
diabetic adult patient; the basal infusion rate is 
defined to support the controller for 
hyperglycemia regulation using the predicted 
glucose level (see (16)). 
 
Tabla 1: Protocol for virtual patients 
 
 




 Breakfast Snack Meal Dinner Snack   
(6:00) (12:00) (15:00) (19:00) (23:00) basal Hbasal 
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The proposed control strategy is tested with the 
ten adults population included in the mentioned 
simulator. For each virtual patient, an RHONN 
identifier is used to estimate the glucose behavior, 
as presented in Fig. 7. The closed-loop behavior is 
presented in Fig. 8, where reference is the desired 
trajectory, which is an ideal patient curve under 
insulin treatment and is compared with the blood 
glucose level in an adults average. In Fig. 9, the 
insulin infusion rate using the fifteen-minutes 
prediction is displayed; for instance, 
hypoglycemic and hyperglycemic case are 
avoided, before 12:00 hrs and after meal intake, at 







































Fig. 9. Closed-loop glucose control for adults 
average with NF-IOC. 
 
 
The Control Variability Grid Analysis (CVGA) is 
a visualization method of the glucose level 
included in the Uva-Padova simulator. Also 
CVGA, the patients are plotted according to X-Y 
coordinates for the minimum and the maximum of 
the glucose reading in the test time lapse. The Fig. 
10 illustrates the test results to the ten adults 
population using the proposed controller, the 
glycemic effectiveness of 100% is achieved. 
 
Fig. 3. Fuzzy set for the control gains. 
Fig. 5. Closed-loop diagram. 
Fig. 6. Closed-loop real connection. 
Fig. 8. Trajectory tracking for adults average 
with NF-IOC. 
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In this paper, T1DM treatment using a novel 
neuro-fuzzy inverse optimal control is described. 
This treatment uses three interlinked strategies to 
regulate glucose level. The first one allows 
estimating the glucose-insulin dynamics. The 
second strategy, a multi-step neuronal predictor is 
used to predict the future glucose data, and the last 
strategy aimes to keep the glucose level into the 
desired trajectory using an inverse optimal control 
approach with fuzzy switching. The controller 
implementation into rapid prototyping board is 
able to keep glucose within normal levels for 24 
hours of treatment on ten adults’ patients. These 
results illustrate the proposed NF-IOC control 
scheme importance for new technologies in order 
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